Polymyalgia Rheumatica Research Studies
The Division of Rheumatology strives to understand and help provide better treatments for Polymyalgia Rheumatica (PMR) through research. Please see the list below which provides a summary of the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease.
| Study Name/IRB#/PI | Brief Description | Basic Eligibility Criteria | Contact |
NOVARTIS IRB# 23-1918 PI: Elena Weinstein, MD
| The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously for 52 weeks in combination with prednisone tapered over 24 weeks in adult participants with PMR who have recently relapsed. To see clinical trials.gov info click here | Eligibility:
| Chong Pedrick 303-724-7518 Najeeb Arishi 303-724-7512 |